Zim Laboratories Ltd
Zim Laboratories Limited is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India.
The company also has wholly owned subsidiaries present overseas which are engaged in the manufacturing & wholesale of pharmaceutical products, market research and research & development activities.
- Market Cap ₹ 463 Cr.
- Current Price ₹ 95.0
- High / Low ₹ 153 / 67.4
- Stock P/E 28.2
- Book Value ₹ 46.4
- Dividend Yield 0.00 %
- ROCE 16.6 %
- ROE 13.0 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 7.88% over past five years.
- Promoter holding is low: 33.3%
- Company has a low return on equity of 9.74% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
266 | 269 | 235 | 273 | 335 | 278 | 307 | 333 | 399 | 355 | |
278 | 239 | 203 | 238 | 293 | 255 | 268 | 292 | 347 | 314 | |
Operating Profit | -12 | 30 | 32 | 35 | 42 | 23 | 40 | 41 | 52 | 41 |
OPM % | -4% | 11% | 13% | 13% | 13% | 8% | 13% | 12% | 13% | 12% |
2 | -2 | 5 | 9 | 2 | 5 | -3 | 4 | 6 | 4 | |
Interest | 10 | 14 | 10 | 9 | 11 | 13 | 11 | 8 | 6 | 6 |
Depreciation | 7 | 9 | 9 | 10 | 11 | 14 | 16 | 16 | 17 | 17 |
Profit before tax | -27 | 5 | 18 | 25 | 22 | 0 | 10 | 21 | 35 | 23 |
Tax % | 19% | 5% | -6% | 23% | 30% | -4,600% | 28% | 31% | 31% | |
-22 | 5 | 19 | 19 | 15 | 3 | 7 | 15 | 24 | 16 | |
EPS in Rs | 3.17 | 0.68 | 1.50 | 2.99 | 5.01 | 3.37 | ||||
Dividend Payout % | 0% | 16% | 4% | 4% | 5% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 13% |
TTM: | -11% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 10% |
3 Years: | 95% |
TTM: | -32% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 18% |
3 Years: | 58% |
1 Year: | 38% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 10% |
Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 |
Reserves | 86 | 91 | 110 | 129 | 135 | 138 | 145 | 159 | 152 | 177 |
93 | 96 | 81 | 81 | 77 | 90 | 82 | 53 | 62 | 62 | |
78 | 61 | 60 | 81 | 100 | 82 | 82 | 112 | 79 | 78 | |
Total Liabilities | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 366 |
87 | 92 | 89 | 94 | 106 | 116 | 107 | 106 | 109 | 121 | |
CWIP | 6 | 3 | 4 | 8 | 13 | 10 | 11 | 12 | 27 | 41 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
172 | 161 | 166 | 196 | 209 | 200 | 208 | 224 | 206 | 204 | |
Total Assets | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 366 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|
22 | 32 | 37 | 35 | 22 | 32 | 49 | 38 | ||
-12 | -7 | -26 | -21 | -19 | -6 | -14 | -35 | ||
-10 | -25 | -10 | -15 | -2 | -26 | -33 | 1 | ||
Net Cash Flow | -0 | -0 | 1 | -1 | 1 | -0 | 2 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 111 | 120 | 137 | 119 | 101 | 89 | 86 | 98 | 87 |
Inventory Days | 93 | 87 | 108 | 134 | 126 | 144 | 125 | 171 | 99 |
Days Payable | 129 | 109 | 137 | 172 | 165 | 168 | 149 | 185 | 107 |
Cash Conversion Cycle | 75 | 99 | 108 | 81 | 63 | 65 | 62 | 85 | 79 |
Working Capital Days | 108 | 111 | 127 | 104 | 83 | 111 | 121 | 104 | 100 |
ROCE % | 13% | 14% | 14% | 15% | 5% | 11% | 12% | 17% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 20 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Mar
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
5 Mar - In compliance with the Regulation 30 of the SEBI (LODR) Regulations, 2015, we would like to inform you about the schedule of the Investors / …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
5 Mar - In compliance with the Regulation 30 of the SEBI (LODR) Regulations, 2015, we would like to inform you about the schedule of the Investors / …
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2019TranscriptNotesPPT
-
Dec 2018TranscriptNotesPPT
Business Overview:[1]
The company develops, manufactures and supplies oral, solid differentiated generic
pharmaceutical formulations and pre-formulation intermediaries (PFI) in certain key therapeutic segments.
The company also provides various delivery solutions that bring differentiation in generic pharmaceutical products through product
conceptualization, product development, filing for registration, manufacture and supply of various pharmaceutical products.